Published ahead of print on June 29, 2006, doi:10.1164/rccm.200510-1667OC Am. J. Respir. Crit. Care Med., Volume 174, Number 6, September 2006, 717-721 A more recent version of this article appeared on September 15, 2006
Submitted on October 25, 2005 Predicting Non-Completion of Treatment for Latent Tuberculous Infection: A Prospective SurveyFred K Shieh1,1 Boston University School of Medicine, Pulmonary Center, Boston, MA, USA, 2 Boston University School of Medicine, Pulmonary Center, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA * To whom correspondence should be addressed. E-mail: jsaukk{at}bu.edu.
Treatment of latent TB infection (LTBI) is essential for the elimination of TB in the United States, but treatment is often not completed. Little is known about patients' reasons for not completing treatment. We hypothesized that certain health beliefs, lifestyle, and clinic- and regimen-related barriers to provision of care could predict non-completion of LTBI treatment.
Methods: We administered a survey in English, Chinese or Spanish to LTBI patients at the first TB clinic visit. Using Key words: Survey, latent, tuberculosis, isoniazid, completion
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 and logistic regression analysis, we assessed demographics, TB risk factors and survey responses as predictors of non-completion of 6 months of isoniazid.
Results: 217 patients, 90% foreign-born, completed the survey, and 28.6% of which finished at least six months of isoniazid under usual clinic conditions. Multivariate analysis identified two independent predictors of non-completion: low risk perception of progressing to active TB without LTBI treatment, OR=0.31 (0.13-0.72, 95% CI), p=0.007, accounting for 20% of non-completers, and not wanting venipuncture, OR = 0.43 (0.22-0.85), 95% CI), p=0.015, accounting for 37% of non-completers. Another 18% shared both predictors, thus these two predictors accounted for 75% of non-completers in total.
Conclusions: Patients assess LTBI treatment risks and inconveniences relative to low perceived benefits at treatment outset. Predictors of LTBI treatment non-completion are identifiable at the first visit. Targeting TB high-risk individuals, minimizing inconveniences, further education, and use of diagnostic tests with improved specificity for TB may address these concerns.
